Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | TOURMALINE-AL1: ixazomib for AL amyloidosis

Angela Dispenzieri • 31 May 2020
Amyloidosis Rare Diseases Cyclophosphamide Dexamethasone Ixazomib Lenalidomide Melphalan Thalidomide
TOURMALINE-AL1

Angela Dispenzieri, MD, of the Mayo Clinic College of Medicine, Rochester, MN, touches on the results of the TOURMALINE-AL1 study (NCT01659658), a randomized study evaluating ixazomib and dexamethasone in the relapsed/refractory amyloid light-chain (AL) amyloidosis setting. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Angela Dispenzieri

Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria
1:53
Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria
Angela Dispenzieri • 6 Sep 2023
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits
2:30
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits
Angela Dispenzieri • 6 Sep 2023
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease
1:42
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease
Angela Dispenzieri • 6 Sep 2023
Rationale behind the watch and wait strategy in smoldering myeloma
1:57
Rationale behind the watch and wait strategy in smoldering myeloma
Angela Dispenzieri • 6 Sep 2023

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Angela Dispenzieri • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Angela Dispenzieri • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Angela Dispenzieri • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Angela Dispenzieri • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals